Episode description
Episode description
Vulnerable plaque and scientific method; industry payments to trainees; tirzepatide or semaglutide; trial interpretation; and PFA are the topics John Mandrola, MD, covers in today’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
I. Non-invasive Imaging for Vulnerable Plaque
PET Imaging Finds Vulnerable Plaques That Cause MI
https://www.medscape.com/viewarticle/pet-imaging-finds-vulnerable-plaques-cause-mi-2024a1000cm2
- JACC paper https://doi.org/10.1016/j.jacc.2024.03.419
- Original JAMA-Card paper https://jamanetwork.com/journals/jamacardiology/fullarticle/2806690
II. Industry Payments to Fellows
- JAMA Network Letter https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2821267
III. GLP-1a Class Effect?
Semaglutide Significantly Improves Chronic Kidney Disease
Mounjaro Beats Ozempic, So Why Isn’t It More Popular?
https://www.medscape.com/viewarticle/mounjaro-beats-ozempic-so-why-isnt-it-more-popular-2024a1000ckd
- JAMA-Internal Medicine: Semaglutide vs Tirzepatide https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2821080
- SELECT trial https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
- FLOW trial https://www.nejm.org/doi/full/10.1056/NEJMoa2403347
- SURPASS-CVOT – Rationale https://doi.org/10.1016/j.ahj.2023.09.007
IV. Colchicine and Trial Interpretation in the Lancet
V. PFA
Pulsed Field Ablation for AF: Are US Electrophysiologists Too Easily Impressed?
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net